Vaxcyte, Inc. Common Stock PCVX
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $117.20 (+111.6% upside)
Key Stats
- Today's Range
- $55.27 – $58.48
- 50-Day Range
- $55.09 – $90.75
- 52-Week Range
- $39.87 – $90.75
- Volume
- 1.91 million shs
- Average Volume
- 1.87 million shs
- Market Cap
- $9.24 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.13%
- Days to Cover
- 1.21
About Vaxcyte, Inc. Common Stock
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Related Stocks
Compare head-to-head: PCVX vs AMGN·PCVX vs MRNA·PCVX vs RGEN·PCVX vs HALO
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
